NAFDAC Speaks on Reported Withdrawal of 101 Medicines, Says Public Misunderstood Advisory

The National Agency for Food and Drug Administration and Control (NAFDAC) has addressed public concerns surrounding reports that 101 pharmaceutical products were withdrawn from circulation in Nigeria. The regulatory body has clarified that the move was not a blanket ban or mass withdrawal as widely misunderstood, but rather a regulatory update in line with international standards and evolving medical guidelines.
Speaking through its Director-General, Prof. Mojisola Adeyeye, the agency explained that the listed drugs were either discontinued due to new scientific evidence, replaced with safer or more effective alternatives, or withdrawn voluntarily by manufacturers following global pharmacovigilance alerts. She stressed that many of these medications had already been phased out of use over time and were no longer in mainstream distribution.
NAFDAC noted that such periodic reviews are a normal part of drug regulation worldwide, especially as newer research provides deeper insight into side effects, risks, or diminishing efficacy of certain products. The agency reassured Nigerians that its primary responsibility remains the protection of public health and that all regulatory decisions are based on rigorous scientific assessment in collaboration with international bodies such as the World Health Organization (WHO) and partner regulatory agencies across the globe.
The alarm raised on social media, the agency added, was largely due to misinterpretation of a technical document that listed drugs no longer recommended for registration or renewal in Nigeria. These decisions, NAFDAC emphasized, are implemented over time and involve due consultation with local manufacturers, importers, and healthcare stakeholders to avoid disruption in medical supply chains.
While urging the public to remain calm, NAFDAC encouraged Nigerians to always seek professional medical advice before using any medication and to report any adverse reactions through its Med Safety App or the nearest agency office. It also warned against the spread of misinformation that could lead to panic or undermine public trust in health regulation.


